Physician profile
John Potomski
NPI 1083657183
$30,950.02
in general payments reported to CMS, 2019-2025
30 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 96% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $493 · 2021: $976 · 2022: $4,105 · 2023: $11K · 2024: $8,521 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $4,796 · Travel and Lodging: $4,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,225.50 |
| Food and Beverage | $4,796.40 |
| Travel and Lodging | $4,054.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15,675.89 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $3,943.65 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $3,282.06 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $2,193.02 | 2022-2023 | Azstarys, Adlarity |
| Sunovion Pharmaceuticals INC. | $643.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $613.42 | 2019-2021 | |
| Smith+Nephew, INC. | $601.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $557.21 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $499.91 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $396.04 | 2023-2025 | Rexulti |
| Sun Pharmaceutical Industries INC. | $353.92 | 2019-2021 | |
| Astellas Pharma US INC | $348.75 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $309.75 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $271.51 | 2023 | Gemtesa, Aptiom |
| Lilly USA, LLC | $249.15 | 2021-2025 | Amyvid, Kisunla, Trulicity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $240.75 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Mylan Specialty L.P. | $199.69 | 2021-2022 | |
| Cvrx, INC. | $106.09 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $84.00 | 2021 | |
| Neurelis, INC. | $62.67 | 2022-2023 | Valtoco |
| Sk Life Science, INC. | $54.27 | 2023 | |
| Ardelyx, INC. | $53.12 | 2024-2025 | Ibsrela |
| Amgen INC. | $47.76 | 2022 | |
| Scilex Pharmaceuticals INC. | $33.62 | 2019 | |
| Urovant Sciences INC | $32.82 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.54 | 2025 | Auvelity |
| Indivior INC. | $19.32 | 2023 | Perseris |
| Kyowa Kirin, INC. | $17.91 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.98 | 2019 | |
| Merck Sharp & Dohme LLC | $13.89 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Potomski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.